Dengue vaccination: Availability and relevance to low- and middle-income countries

Sitaram Khadka; Niken Paudel; Kabin Maleku; Sadhana Dahal; Santoshi Giri

doi:10.4103/apjtm.apjtm_259_25

Asian Pacific Journal of Tropical Medicine ›› 2025, Vol. 18 ›› Issue (12) :525 -527. DOI: 10.4103/apjtm.apjtm_259_25

Perspective

research-article

Dengue vaccination: Availability and relevance to low- and middle-income countries

Author information +

History +

PDF (207KB)

Cite this article

Download citation ▾

Sitaram Khadka, Niken Paudel, Kabin Maleku, Sadhana Dahal, Santoshi Giri. Dengue vaccination: Availability and relevance to low- and middle-income countries. Asian Pacific Journal of Tropical Medicine, 2025, 18 (12) : 525-527 DOI:10.4103/apjtm.apjtm_259_25

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	World Health Organization. Dengue-Global situation. 2023. [Online]. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON498. [Accessed on 10 November 2024].

[2]	Sahu MC, Samantaray RK, Pal A, Pati S. Recent advances on pathogenesis, diagnosis, prevention, immunological aspects, and vectors of dengue: A review. Asian Pac J Trop Biomed 2023; 13(8): 325-338.

[3]

The United States Food and Drug Administration. First FDA-approved vaccine for the prevention of dengue disease in endemic regions. 2019. [Online]. Available from: https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-dengue-disease-endemic-regions. [Accessed on 10 November 2024].

[4]	World Health Organization. WHO prequalifies new dengue vaccine. [Online]. Available from: https://www.who.int/news/item/15-05-2024-who-prequalifies-new-dengue-vaccine. [Accessed on 10 November 2024].

[5]	Papapetropoulos A, Topouzis S, Alexander SP, Cortese‐Krott M, Kendall DA, Martemyanov KA, et al. Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review. Br J Pharmacol 2024; 181(11): 1553-1575.

[6]	Reuters . Takeda withdraws US application for dengue vaccine candidate. 2023. [Online]. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/takeda-withdraws-us-application-dengue-vaccine-candidate-2023-07-11/. [Accessed on 10 November 2024].

[7]	Silva JP, Fernandez-Sesma A. Challenges on the development of a dengue vaccine: A comprehensive review of the state of the art. J Gen Virol 2023; 104(3): 001831.

[8]	Halstead SB, Katzelnick LC, Russell PK, Markoff L, Aguiar M, Dans LR, et al. Ethics of a partially effective dengue vaccine: Lessons from the Philippines. Vaccine 2020; 38(35): 5572.

[9]	Dengvaxia . European Medicines Agency (EMA). 2023. [Online]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/dengvaxia. [Accessed on 10 November 2024].

[10]	The Straits Times. Price for Malaysia’s first dengue vaccine soars. 2024. [Online]. Available from: https://www.straitstimes.com/asia/se-asia/price-for-malaysia-s-first-dengue-vaccine-soars. [Accessed on 10 November 2024].

[11]	World Bank. GDP per capita (current US$)-Nepal. 2024. [Online]. Available from: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=NP. [Accessed on 10 November 2024].

[12]	Govindasamy D, Vijalakashmi G, Vijayakumar B, Rahul A. Assessment of public perspectives and barriers towards dengue preventive practices using the Health Belief Model in Puducherry, India: A cross-sectional study. Asian Pac J Trop Med 2024; 17(8): 358-368.